A 6-month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Middle Eastern and North African men with erectile dysfunction

Current Medical Research and Opinion

Volumn 29, Issue 6, 2013, Pages 707-717

  El Meliegy, Amr ^a   Rabah, Danny ^b   Al Mitwalli, Kutaiba ^c   Mostafa, Taymour ^d   Hussein, Tarek ^e   Istarabadi, Mohamed ^f   Lei, Yao ^g   Gurbuz, Sirel ^g  

^a DR SOLIMAN FAKEEH HOSPITAL   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c Dallah Hospital   (Saudi Arabia)

^d CAIRO UNIVERSITY   (Egypt)

^e ALEXANDRIA UNIVERSITY   (Egypt)

^f Al Zahraa Hospital   (United Arab Emirates)

^g ELI LILLY AND COMPANY   (United States)

Author keywords

Adherence; Erectile dysfunction; PDE5 inhibitors; Persistence; Sildenafil; Tadalafil; Vardenafil

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL; VARDENAFIL;

ADULT; AGE; ARTICLE; BODY MASS; DISEASE SEVERITY; EGYPT; EMPLOYMENT; ERECTILE DYSFUNCTION; HUMAN; INTERNATIONAL INDEX OF ERECTILE FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PROSPECTIVE STUDY; SAUDI ARABIA; UNITED ARAB EMIRATES;

CARBOLINES; EGYPT; ERECTILE DYSFUNCTION; HUMANS; IMIDAZOLES; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PROSPECTIVE STUDIES; PURINES; QUESTIONNAIRES; SAUDI ARABIA; SELF CONCEPT; SULFONES; TREATMENT OUTCOME; TRIAZINES; UNITED ARAB EMIRATES;

EID: 84877271984     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.791263     Document Type: Article

References (21)

1. Chen KK, Jiann BP, Lin JS, et al. Efficacy and safety of on-demand oral tadalafil in the treatment of men with erectile dysfunction in Taiwan: a randomized, double-blind, parallel, placebo-controlled clinical study. J Sex Med 2004;1:201-8
2. Rodriguez VL, Lledo GE, Rajmil O, et al. [Tadalafil vs sildenafil patient preference in Spanish men with erectile dysfunction: results from an International Multicentric Study]. Actas Urol Esp 2006;30:67-79
3. Hatzichristou D, Montorsi F, Buvat J, et al. The efficacy and safety of flexibledose vardenafil (levitra) in a broad population of European men. Eur Urol 2004;45:634-41
4. Porst H, Padma-Nathan H, Giuliano F, et al. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology 2003;62:121-5
5. Rosen RC, Shabsigh R, Kuritzky L, et al. The efficacy of tadalafil in improving sexual satisfaction and overall satisfaction in men with mild, moderate, and severe erectile dysfunction: a retrospective pooled analysis of data from randomized, placebo-controlled clinical trials. Curr Med Res Opin 2005;21:1701-9
6. Rubio-Aurioles E, Kim ED, Rosen RC, et al. Impact on erectile function and sexual quality of life of couples: a double-blind, randomized, placebo-controlled trial of tadalafil taken once daily. J Sex Med 2009;6:1314-23
7. Skoumal R, Chen J, Kula K, et al. Efficacy and treatment satisfaction with on-demand tadalafil (Cialis) in men with erectile dysfunction. Eur Urol 2004;46:362-9
8. von Keitz A, Rajfer J, Segal S, et al. A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil. Eur Urol 2004;45:499-507
9. Hassan A, El-Hadidy M, El-Deeck BS, et al. Couple satisfaction to different therapeutic modalities for organic erectile dysfunction. J Sex Med 2008;5:2381-91
10. Mulhall JP, McLaughlin TP, Harnett JP, et al. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction. J Sex Med 2005;2:848-55
11. Roumeguere T, Verheyden B, Arver S, et al. Therapeutic response after first month of tadalafil treatment predicts 12 months treatment continuation in patients with erectile dysfunction: results from the DETECT study. J Sex Med 2008;5:1708-19
12. Gruenwald I, Shenfeld O, Chen J, et al. Positive effect of counseling and dose adjustment in patients with erectile dysfunction who failed treatment with sildenafil. Eur Urol 2006;50:134-40
13. Hatzichristou D, Moysidis K, Apostolidis A, et al. Sildenafil failures may be due to inadequate patient instructions and follow-up: a study on 100 non-responders. Eur Urol 2005;47:518-22
14. Hatzimouratidis K, Moysidis K, Bekos A, et al. Treatment strategy for 'nonresponders' to tadalafil and vardenafil: a real-life study. Eur Urol 2006;50:126-32
15. Jiann BP, Yu CC, Su CC, et al. Compliance of sildenafil treatment for erectile dysfunction and factors affecting it. Int J Impot Res 2006;18: 146-9
16. Klotz T, Mathers M, Klotz R, et al. Why do patients with erectile dysfunction abandon effective therapy with sildenafil (Viagra) Int J Impot Res 2005;17:2-4
17. Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822-30
18. Althof SE, Corty EW, Levine SB, et al. EDITS: development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction. Urology 1999;53:793-9
19. Cappelleri JC, Althof SE, Siegel RL, et al. Development and validation of the Self-Esteem And Relationship (SEAR) questionnaire in erectile dysfunction. Int J Impot Res 2004;16:30-8
20. Mulhall JP, Goldstein I, Bushmakin AG, et al. Validation of the erection hardness score. J Sex Med 2007;4:1626-34
21. Roumeguere T, Verheyden B, Arver S, et al. Therapeutic response after first month of tadalafil treatment predicts 12 months treatment continuation in patients with erectile dysfunction: results from the DETECT study. J Sex Med 2008;5:1708-19